ArriVent BioPharma (AVBP) Expected to Announce Earnings on Thursday

ArriVent BioPharma (NASDAQ:AVBP) is expected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.18. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Stock Performance

AVBP stock opened at $18.99 on Wednesday. ArriVent BioPharma has a fifty-two week low of $14.35 and a fifty-two week high of $36.37. The company has a market capitalization of $645.96 million, a price-to-earnings ratio of -7.39 and a beta of 1.00. The business’s 50 day moving average price is $24.70 and its two-hundred day moving average price is $26.62.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. B. Riley initiated coverage on ArriVent BioPharma in a research note on Thursday, March 20th. They issued a “buy” rating and a $37.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $39.00 price target on shares of ArriVent BioPharma in a research note on Friday, March 7th. Finally, Guggenheim began coverage on shares of ArriVent BioPharma in a research report on Monday, March 10th. They set a “buy” rating and a $45.00 price target for the company. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, ArriVent BioPharma presently has an average rating of “Buy” and an average target price of $39.00.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.